Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
The presentations are as follows:
Oral Presentation – Lecture Hall 3a (14:54 – 15:06)
- O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano
Poster Presentations – New antimicrobials against Gram-positives (13:30 – 14:30)
P 1091: Effects of food on the pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry,
C. R. Bethune
P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus; S. Lemaire,
K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
- P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
- P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J.
Locke, K. Shaw
P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J.
Locke, K. Shaw
Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius’ pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
SOURCE Trius Therapeutics, Inc.